Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2014 | Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL

Ian Flinn • 5 Dec 2014
ASH 2014
Chronic Lymphocytic Leukemia Antibodies Obinutuzumab

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the preliminary results of a phase Ib study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL).

More from Ian Flinn

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL 2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
Unanswered questions in frontline CLL treatment 0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
Umbralisib and ublituximab in patients with CLL and comorbidities 1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
Debulking strategies in CLL before venetoclax therapy 2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL 2:08
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
Jennifer Woyach • 8 Dec 2025
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314 2:54
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals